Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Telios Pharmaceuticals

Executive Summary

Ono Pharmaceutical Co. Ltd. (Osaka) acquires "significant equity investment" and is supplying "several million dollars" to privately held San Diego-based R&D firm to develop Transforming Growth Factor-beta-based drugs. Ono will fund R&D and clinical testing of TGFb drugs that block "abnormal tissue scarring involved in kidney inflammation, pulmonary fibrosis, liver cirrhosis and other fibrotic disorders" in return for marketing rights in Japan, Taiwan and South Korea. Telios retains rights elsewhere. Agreement also gives Ono first right of refusal in the same countries for all other Telios human drug products -- excluding firm's blood-clot inhibitors and (ITALICS)Telio-derm(END ITALICS) wound healing gel ("The Pink Sheet" Aug. 13, T&G-9). Ono already has Asian license for Telios' "dry eye" product (ITALICS)Oculos,(END ITALICS) which is in development.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts